MetaCap

Legend Biotech (LEGN) vs SELLAS Life Sciences Group (SLS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

SELLAS Life Sciences Group (SLS) has outperformed Legend Biotech (LEGN) over the past year, gaining 792.8% versus a loss of 45.9%. Over five years, SLS leads with a +94.0% price change compared with -71.8% for LEGN. Legend Biotech is the larger company by market cap ($2.96 billion vs $2.78 billion), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

LEGN-45.86%SLS+792.81%
+1212%+553%-106%
Nov 21, 20251 yearNov 20, 2026
LEGN-72.40%SLS+94.86%
+131%+14%-103%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

LEGN versus SLS key metrics
MetricLEGNSLS
Share price$15.25$13.66
Market cap$2.96B$2.78B
1-day change-5.28%-8.08%
YTD return-29.85%+262.33%
1-year return-45.86%+792.81%
5-year return-71.83%+94.03%
Forward P/E28.89—
EPS (TTM)$-0.02$-0.20
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$1.03B—
Revenue growth (YoY)+64.04%—
Net income (latest FY)$-296.80M$-26.86M
Gross margin61.41%—
Operating margin-13.27%—
Net margin-28.85%—
52-week high$37.50$24.89
52-week low$15.15$1.39
Distance from 52-week high-59.33%-45.12%
Analyst consensusbuystrong_buy
Avg. price target upside+168.39%+137.92%
Average volume2.26M9.64M
Shares outstanding193.97M203.86M
Employees3,30013
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • SLS has outperformed LEGN by 838.7 percentage points over the past year.

About Legend Biotech

LEGN stock →

Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM).

Health Care · Biotechnology: Pharmaceutical Preparations · 3,300 employees

About SELLAS Life Sciences Group

SLS stock →

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees

LEGN vs SLS FAQ

Which is bigger, Legend Biotech or SELLAS Life Sciences Group?

Legend Biotech (LEGN) is larger, with a market capitalization of $2.96B compared with $2.78B for SELLAS Life Sciences Group (SLS).

Which stock has performed better over the past year, LEGN or SLS?

SLS returned +792.81% over the past 12 months, compared with -45.86% for LEGN (price return, excluding dividends). Past performance does not predict future results.

Are Legend Biotech and SELLAS Life Sciences Group in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons